Our first quarter edition features leading insights from subject matter experts covering a range of scientific topics, including the growth of the microbiome field, advanced therapies, epigenetics, RNA biomarkers for cancer, drug delivery via silica nanoparticles, artificial intelligence, and the path to wellness through cannabis.
The Pharma's Almanac editorial team tackles some of the major M&A transactions in recent history and puts them into perspective.
Nice Insight's Nigel Walker uses recent M&A activity in the pharmaceutical industry to illuminate significant issues in industry dynamics.
Kurt R. Nielsen, President and CEO of Pii, discusses how the company has refocused its business as a dedicated CDMO, applying its pharmaceutics expertise and deep product knowledge.
Kyle Zingaro, Deborah Mar Begos, and Todd Miller of Thermo Fisher Scientific's Viral Vector Services team relate the unique challenges in process validation for viral vector manufacturing.
Chief Executive Officer Frank Mathias explain's Rentschler Biopharma SE's vision and strategy for the future of the company as a leading global CDMO.
An expanded line of mannitol excipients simplifies the manufacturing of patient-friendly dosage forms, according to SPI Pharma's Bill McCarthy and Graeme McLeod.
In this virtual panel, six experts spanning the operations at Grifols Recombinant Protein CDMO discuss how they are leveraging their history and expertise to support the contract development and manufacturing of therapeutic proteins.
Arranta Bio's Chief Scientific Officer Aaron B. Cowley relates the lessons learned during a decade exploring the microbiome and what that means for the future of the Arranta and the microbiome field.
Servier's Patrice Martin describes the critical services and commitments that make an effective CDMO.
James Springer, Mitch Kenyon, Tyler Kerr, and James Goodwin of Albemarle Fine Chemistry Services explain how small-volume manufacturing capabilities support tech transfer and scale-up.
Marc Boyle, Co-President of Boyle Transportation, discusses how the company's proprietary tracking and visibility portal reinforces Boyle's security commitment.
Antonio A. Gómez, Pharmaceutical Production Senior Manager at Laboratorios Grifols, explains the critical role of continuous improvement in the manufacturing of parenteral drugs.
Jonathan Reis, President and CEO of Censa Pharmaceuticals, describes the company's novel approach developing therapeutics to treat phenylketonuria and primary BH4 deficiency.
Vacuum compression molding presents a novel and attractive small-scale screening technology for amorphous solid dispersions, according to Daniel Treffer, founder and CEO of MeltPrep.
Immuneering Corporation's Disease Cancelling Technology enables the discovery of drug candidates that have eluded conventional methods, explains co-founder and CEO Ben Zeskind.
Ron Andrews, President and CEO of Oncocyte, explains how RNA biomarkers can facilitate early diagnosis of lung cancers.
Alexis Peyroles, CEO of OSE Immunotherapeutics, details the company's approach to R&D for the development of therapeutics targeting immune checkpoints and autoimmune diseases.
We discuss the potential of off-the-shelf natural killer cell-based therapies for cancer treatment with Patrick Soon-Shiong, Chairman and CEO of NantKwest.
BioVectra's Scott Doncaster, Renaud Jacquemart, and Clarke MacDonald explain the importance of process engineering to commercial-scale manufacturing of complex APIs.
CEO Alex Ovadia explain's how Check-Cap's prep-free, scanning capsule-based screening system can increase adherence compared with conventional colonoscopy approaches.
Silica nanoparticles show considerable promise for delivery of oligonucleotide drugs, according to Nigel Theobald, CEO of N4 Pharma.
BioXcel Therapeutics' co-founder, Chairman, and CEO Vimal Mehta explains the role of artificial intelligence in drug re-innovation.
Non-human primates are key to establishing a link between the human immune system and the microbiome, explains Hughes Contamin, founder and CEO of Cynbiose.
Jigar Raythatha, President and CEO of Constellation Pharmaceuticals, discusses the potential of targeting epigenetic regulators for cancer therapies.
We discuss the role of high-pressure technologies in R&D, drug development, and CBD products with Richard T. Schumacher, Chairman and CEO of Pressure BioSciences.
CPhI and P-Mec China offers an opportunity to understand and connect with pharma companies in the region.
Erica Sosnowski and Adam Sosnowski of Sosna + Co. explain the keys to successful licensing and partnering.
Achim Newrzella, Vice President of Results Healthcare, relates some of the major findings from the firm's exploration of outsourced pharmaceutical manufacturing trends.
Matt Hicks, COO and Counsel of Federal Equipment Company, makes recommendations for companies faced with surplus equipment following the cancellation of capital projects.
Baker McKenzie's Randy Sunberg discusses trends and evolving models for M&A and licensing transactions.
Joe Carleone, Managing Director of Carleone Partners, stresses the importance of middle management in successful M&A outcomes.
ForDoz Pharma CEO James He describes the novel challenges in development and manufacturing of complex injectable drugs.
Disruptive industrial technologies will be key to growth in the advanced therapies market, according to Daniella Kranjac and Gustavo Mahler of Dynamk Capital.
Stefan Beyer and Kai Lipinski of Vibalogics tackle the unique expertise and technologies needed to support the development and manufacturing of oncolytic viruses.
Ed Price, President and CEO of Seqens-North America, explores some of the major drivers of change in the evolving pharma industry.
Nice Insight's Nigel Walker relates his plans for a cross-continental road trip to explore healthcare in Europe in the run-up to CPhI Worldwide 2020 in Milano, Italy.
Pharma's Almanac explores the health status and healthcare systems across Europe.
The That's Nice team remembers their road trip across the United States culminating in BIO International 2017.
Pii continuously adds offerings at small and medium scale for clinical trial and commercial manufacturing for both oral and parenteral drug delivery technologies.
Federal Equipment Company’s core mission continues to be sourcing equipment through services that help companies manage surplus equipment.
SGD Pharma is constantly working to improve the level of service for customers for the development of new products or the regulatory, laboratory, quality, and logistics support they offer.
After a string of recent acquisitions, Olon has updated the company mission and vision to reflect goals for 2020 and beyond.
Arranta Bio has recently committed to a $100M investment in their facilities to build end-to-end microbiome capacity.
Avara’s mission is to provide world-class outsourcing services to help deliver life-changing and life-saving medicines to the patients who need them.
SanaClis is proud to offer a comprehensive range of services for clinical trials and ensures an efficient drug development process for pharma and biotech companies.
SPI Pharma’s mission is making a difference — in the lives of patients, their customers, their employees. and the communities that they serve.
TriRx is differentiating itself in the marketplace and creating significant growth opportunities for the company.
Avara Pharmaceutical Services CEO Larry P. Lee explains how the company has refocused on its core capabilities of OSD and sterile products.
Nice Insight's Research Director TJ Ladage discusses the therapeutic promise and the reality of CRISPR gene editing.
The Future of the CDMO Market: The Art of the Possible; Tim Tyson; TriRx Pharmaceutical Services
Building an Entrepreneurial Society in Scotland; Sandy Kennedy; Entrepreneurial Scotland
Peter Barsoom and Erin Holzer of 1906 discuss the company's new line of functional cannabis products.
Shailesh Maingi, CEO and founder of Kineticos, highlights some of the primary opportunities and challenges ahead for the commercialization of cell and gene therapies.
Haig Armaghanian, founder and CEO of Haig Barrett, Inc., suggests that jumpstarting innovation is key to the future of life sciences in the UK following Brexit.
For That’s Nice’s 25th anniversary, Nigel Walker and the team are preparing to face the future of healthcare by looking backward.
A panel of SMEs characterize the M&A landscape in the pharma/biopharma industry.
A range of experts speculate on the technologies likely to lead the industry in the coming decade.
Nice Insight's Cynthia Challener explores the state of diversity and inclusion in the industry, advances that have been made, and the challenges ahead.